<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00788931</url>
  </required_header>
  <id_info>
    <org_study_id>CLBH589C2114</org_study_id>
    <secondary_id>2007-004788-23</secondary_id>
    <nct_id>NCT00788931</nct_id>
  </id_info>
  <brief_title>A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer</brief_title>
  <official_title>A Phase Ib, Open-label, Two Arm Study of i.v. and Oral Panobinostat (LBH589) in Combination With i.v. Trastuzumab (Herceptin®) and i.v. Paclitaxel as Treatment for Adult Female Patients With HER2 Overexpressing Metastatic Breast Cancer (MBC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to identify the maximum tolerated dose (MTD) of both
      intravenous and oral panobinostat when given in combination with trastuzumab and paclitaxel.
      The study will evaluate safety and efficacy of the combination in adult female patients with
      HER2+ metastatic breast cancer
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the maximum tolerated dose of oral panobinostat in combination with trastuzumab and paclitaxel. Determine the maximum tolerated dose of iv LBH in combination with trastuzumab and paclitaxel.</measure>
    <time_frame>At least 21 day cycle for both arms</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability throughout the study for both IV and oral arms to determine the recommended dose for phase ll trials.</measure>
    <time_frame>4 weeks after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy in the expansion phase of the trial when the MTD is defined.</measure>
    <time_frame>throughout the study and 4 weeks after end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>HER-2 Positive Breast Cancer</condition>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>IV LBH589 + trastuzumab + paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>i.v. panobinostat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral LBH589 + trastuzumab + paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral panobinostat</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV LBH589</intervention_name>
    <arm_group_label>IV LBH589 + trastuzumab + paclitaxel</arm_group_label>
    <arm_group_label>Oral LBH589 + trastuzumab + paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral LBH589</intervention_name>
    <arm_group_label>Oral LBH589 + trastuzumab + paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <arm_group_label>IV LBH589 + trastuzumab + paclitaxel</arm_group_label>
    <arm_group_label>Oral LBH589 + trastuzumab + paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <arm_group_label>IV LBH589 + trastuzumab + paclitaxel</arm_group_label>
    <arm_group_label>Oral LBH589 + trastuzumab + paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 year old

          -  Confirmed HER2+ metastatic breast cancer

          -  Prior treatment and progression on trastuzumab

          -  Patients must have adequate organ functions

          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1

        Exclusion Criteria:

          -  Patients who have had surgery within last 2 weeks prior to starting the treatment

          -  Patients who receive concurrent therapy for brain metastases

          -  Impaired heart function or clinically significant heart disease

          -  Ongoing diarrhea

          -  Liver or renal disease with impaired hepatic or renal functions

          -  Concomitant use of any anti-cancer therapy or certain drugs

          -  Female patients who are pregnant or breast feeding

          -  Patients not willing to use an effective method of birth control Other
             protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36688</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Macerata</city>
        <state>MC</state>
        <zip>62100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aviano</city>
        <state>PN</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Russian Federation</country>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2008</study_first_submitted>
  <study_first_submitted_qc>November 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2008</study_first_posted>
  <last_update_submitted>November 26, 2012</last_update_submitted>
  <last_update_submitted_qc>November 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>HER2 positive</keyword>
  <keyword>adult-female</keyword>
  <keyword>LBH589</keyword>
  <keyword>HDAC inhibitor</keyword>
  <keyword>panobinostat</keyword>
  <keyword>metastatic breast</keyword>
  <keyword>adult female patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Panobinostat</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

